These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28486001)

  • 21. Emerging resistance in Gram-negative pathogens and implications for clinical practice.
    Cantón R; Lumb J
    Future Microbiol; 2011 Jan; 6(1):19-22. PubMed ID: 21162632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens.
    Scaglione F; Paraboni L
    Int J Antimicrob Agents; 2008 Oct; 32(4):294-301. PubMed ID: 18621508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria.
    Klastersky J; Georgala A
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):268-78. PubMed ID: 25151213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
    Zavascki AP
    Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of β-lactams resistance in Gram-negative bacteria in Tunisia.
    Chouchani C; Marrakchi R; El Salabi A
    Crit Rev Microbiol; 2011 Aug; 37(3):167-77. PubMed ID: 21438848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.
    Vasoo S; Barreto JN; Tosh PK
    Mayo Clin Proc; 2015 Mar; 90(3):395-403. PubMed ID: 25744116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.
    Siopi M; Skliros D; Paranos P; Koumasi N; Flemetakis E; Pournaras S; Meletiadis J
    Clin Microbiol Rev; 2024 Sep; 37(3):e0004424. PubMed ID: 39072666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymyxins: a review of the current status including recent developments.
    Kwa AL; Tam VH; Falagas ME
    Ann Acad Med Singap; 2008 Oct; 37(10):870-83. PubMed ID: 19037522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Chua HC; Tse A; Smith NM; Mergenhagen KA; Cha R; Tsuji BT
    Int J Antimicrob Agents; 2021 Mar; 57(3):106269. PubMed ID: 33358761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children.
    Rose L; Coulter MM; Chan S; Hossain J; Di Pentima MC
    Pediatr Infect Dis J; 2014 Jun; 33(6):e158-61. PubMed ID: 24830523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.
    Sy SK; Zhuang L; Derendorf H
    Expert Opin Drug Metab Toxicol; 2016; 12(1):93-114. PubMed ID: 26652832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calculated antibiotic therapy in gastroenterologic infections].
    Braun RW
    Praxis (Bern 1994); 2003 Aug; 92(33):1343-9. PubMed ID: 14502790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-spectrum beta-lactamases: a brief clinical update.
    Malloy AM; Campos JM
    Pediatr Infect Dis J; 2011 Dec; 30(12):1092-3. PubMed ID: 22105419
    [No Abstract]   [Full Text] [Related]  

  • 38. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
    Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
    Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: a patent review (2009-2012).
    Supuran CT; Carta F; Scozzafava A
    Expert Opin Ther Pat; 2013 Jul; 23(7):777-88. PubMed ID: 23458841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?
    Monogue ML; Nicolau DP
    Expert Rev Anti Infect Ther; 2019 Aug; 17(8):571-582. PubMed ID: 31340665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.